Conrad Siegel Investment Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$420K Buy
350
+6
+2% +$6.13K 0.07% 51
2026
Q1
$316K Buy
344
+6
+2% +$6.08K 0.06% 52
2025
Q4
$363K Buy
338
+16
+5% +$15.3K 0.07% 48
2025
Q3
$246K Buy
322
+21
+7% +$15.6K 0.05% 51
2025
Q2
$235K Sell
301
-28
-9% -$21.8K 0.05% 50
2025
Q1
$272K Buy
329
+34
+12% +$28.3K 0.07% 42
2024
Q4
$228K Sell
295
-23
-7% -$19K 0.06% 41
2024
Q3
$282K Sell
318
-1
-0.3% -$899 0.08% 37
2024
Q2
$289K Buy
319
+22
+7% +$17.6K 0.08% 38
2024
Q1
$231K Buy
+297
New +$211K 0.07% 36

Other funds holding LLY

Conrad Siegel Investment Advisors's LLY Position: Q2 2026 in Review

Conrad Siegel Investment Advisors increased its Eli Lilly (LLY) stake by 1.7% in Q2 2026, buying an estimated $6.13K and bringing the position to 350 shares worth $420K. The position accounts for 0.07% of the portfolio, ranked #51.

Conrad Siegel Investment Advisors first reported a position in LLY in Q1 2024 and has held it in 10 quarters since. 1,558 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Conrad Siegel Investment Advisors held 350 shares of Eli Lilly worth $420K as of Q2 2026.
  • Conrad Siegel Investment Advisors bought 6 Eli Lilly shares in Q2 2026, an estimated $6.13K.
  • Eli Lilly made up 0.07% of Conrad Siegel Investment Advisors's portfolio in Q2 2026, its #51 holding.
  • Conrad Siegel Investment Advisors first reported a position in Eli Lilly in Q1 2024 and has held it in 10 quarters since.
  • 1,558 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Conrad Siegel Investment Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.